Showing 1521-1530 of 2152 results for "".
- BVI Completes Enrollment of Finevision HP IDE Clinical Studyhttps://modernod.com/news/bvi-completes-enrollment-of-finevision-hp-ide-clinical-study/2481581/BVI announced it has completed enrollment of its US Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal IOL, Finevision HP. The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, rand
- Keranova Announces Clinical Study Results for Robotic Laser Technologyhttps://modernod.com/news/keranova-announces-clinical-study-results-for-robotic-laser-technology/2481345/Keranova announced the finalization of the regulatory clinical studies of FemtoMatrix, its robotic laser technology. With the positive results, the company said it will now apply for CE marking for this new class of surgical equipment in cataract surgery. According to Ker
- CooperVision MiSight 1 Day Officially Launches in Chinahttps://modernod.com/news/coopervision-misight-1-day-officially-launches-in-china/2481026/CooperVision and EssilorLuxottica have officially launched MiSight 1 day contact lenses in China, marking its availability in the world’s largest country for myopia management. It is the first product of any type that has an indication from the Chinese National Medical Products Adminis
- Alcon Celebrates 75th Anniversaryhttps://modernod.com/news/alcon-celebrates-75-years-of-eye-care-innovation/2480862/Alcon marked the company’s 75th anniversary this week with its "Brilliant History. Brilliant Future." celebration. On May 16, 1947, Alcon Laboratories Inc. was incorporated and began manufacturing specialty pharmaceutical products in Fort Worth, Texas. To
- Schwind Celebrates 30 Years in Refractive Corneal Surgeryhttps://modernod.com/news/schwind-celebrates-30-years-in-refractive-corneal-surgery/2480804/In 2022, Schwind eye-tech-solutions is celebrating a milestone, as the company marks 30 years of driving solutions for refractive corneal surgery. During this period, Schwind has expanded its treatment options for eye surgeons and patients. Founded in 1958 and initially a successful one-stop supp
- Panelists Named for “Making Contact Lens Compliance Stick” Eventshttps://modernod.com/news/panelists-named-for-making-contact-lens-compliance-stick-events/2480644/Four highly regarded optometrists have been named as panelists for a pair of Contact Lens Institute online learning events scheduled for March 3. Drs. Chris Lievens, Mark Schaeffer, Bridgitte Shen Lee, and Jason Tu will headline “
- FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Wet AMD and DMEhttps://modernod.com/news/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-wet-amd-and-dme/2480603/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye. Vabysmo is also the first and only FDA-approved inj
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Hanita Lenses Launches New Website as Part of 40th Anniversaryhttps://modernod.com/news/hanita-lenses-launches-new-website-as-part-of-40th-anniversary/2480365/Hanita Lenses has marked its 40th anniversary by launching a new website as part of its rebranding. Israel-based Hanita Lenses is a manufacturer and provider of intraocular lens solutions for cataract surgery.
- Oyster Point Pharma Receives FDA Approval of Tyrvaya Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-receives-fda-approval-of-tyrvaya-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2480356/Oyster Point Pharma announced that the FDA has approved Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. The approval marks the first and only nasal spray approved for the treatment of dry eye disease. Tyrvaya&n